Endpoints: GreenLight licenses mRNA shingles vaccine

“GreenLight’s approach resonates with our mission to make healthcare equitable for all,” SII CEO Adar Poonawalla said in a statement. “Messenger RNA technology will play a key role in reducing the burden of human suffering caused by vaccine-preventable diseases across LMICs.”

There is an option to expand the license to two additional vaccines or therapies to be named later, GreenLight said in a release, and the shingles vaccine manufacturing process will be transferred to the SII facility in Pune, India.

Read the full article here.

Find out more about how GreenLight manufactures RNA.